Cotransfection of poly(I: C) and siRNA of IL-10 into fusions of dendritic and glioma cells enhances antitumor T helper type 1 induction in patients with glioma

Journal of Immunotherapy

Volumn 34, Issue 2, 2011, Pages 121-128

  Akasaki, Yasuharu ^a   Kikuchi, Tetsuro ^a   Irie, Masaki ^a   Yamamoto, Yohei ^a   Arai, Takao ^a   Tanaka, Toshihide ^a   Joki, Tatsuhiro ^a   Abe, Toshiaki ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

dendritic cell; glioma; polyriboinosinic polyribocytidylic acid; small interference RNA; Th1

Indexed keywords

BETA INTERFERON; DENDRITIC CELL VACCINE; INTERLEUKIN 10; INTERLEUKIN 10 SMALL INTERFERING RNA; INTERLEUKIN 12P70; PADELIPORFIN; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FUSION CELL; GENETIC TRANSFECTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TH1 CELL;

CELL FUSION; CELL LINE, TUMOR; DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; RNA, SMALL INTERFERING; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFECTION;

EID: 79953059547     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181e5c278     Document Type: Article

References (33)

1. Gunzer M, Janich S, Varga G, et al. Dendritic cells and tumor immunity. Semin Immunol. 2001;13:291-302. (Pubitemid 32744580)
2. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245-252. (Pubitemid 28155090)
3. Zitvogel L, Mayordomo J, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;183:87-97. (Pubitemid 26028748)
4. Tuting T, Wilson C, Martin D, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T-cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol. 1998;160:1139-1147. (Pubitemid 28093408)
5. Celluzzi C, Falo LJ. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol. 1998;160:3081-3085. (Pubitemid 28164693)
6. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561. (Pubitemid 27198656)
7. Steinman R, Hawiger D, Nussenzweig M. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711. (Pubitemid 37174545)
8. Medzhitov R, Janeway CJ. Innate immune recognition: mechanisms and pathways. Immunol Rev. 2000;173:89-97. (Pubitemid 30095213)
9. Lapteva N, Seethammagari M, Hanks B, et al. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007;67:10528-10537. (Pubitemid 350070829)
10. Kortylewski M, Kujawski M, Herrmann A, et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res. 2009;69:2497-2505.
11. Verdeil G, Marquardt K, Surh C, et al. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci USA. 2008;105: 16683-16688.
12. Alexopoulou L, Holt A, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Tolllike receptor 3. Nature. 2001;413:732-738. (Pubitemid 33009951)
13. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 2008; 60:805-812.
14. Verdijk R, Mutis T, Esendam B, et al. Polyriboinosinic poly-ribocytidylic acid [poly(I:C)] induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163:57-61. (Pubitemid 29295824)
15. Fujimura T, Nakagawa S, Ohtani T, et al. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol. 2006; 36:3371-3380. (Pubitemid 44932738)
16. Akasaki Y, Kikuchi T, Homma S, et al. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother. 2001;24:106-113. (Pubitemid 32183056)
17. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50:337-344. (Pubitemid 32835343)
18. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombi-nant human interleukin 12. J Immunother. 2004;27:452-459. (Pubitemid 39447353)
19. Moore K, de Waal Malefyt R, Coffman R, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001; 19:683-765. (Pubitemid 32368050)
20. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3: 133-146. (Pubitemid 37328691)
21. Butterfield L, Gooding W, Whiteside T. Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother. 2008;31:89-100. (Pubitemid 351619408)
22. Corinti S, Albanesi C, la Sala A, et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol. 2001; 166:4312-4318. (Pubitemid 32233711)
23. + T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol. 2004;173:4352-4359. (Pubitemid 39280663)
24. Liu G, Ng H, Akasaki Y, et al. Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur J Immunol. 2004;34:1680-1687. (Pubitemid 39256050)
25. Gautier G, Humbert M, Deauvieau F, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med. 2005;201:1435-1446. (Pubitemid 40664087)
26. Bochtler P, Kroger A, Schirmbeck R, et al. Type I IFN-induced, NKT cell-mediated negative control of CD8 T-cell priming by dendritic cells. J Immunol. 2008;181:1633-1643.
27. Gately M, Renzetti L, Magram J, et al. The interleukin-12/ interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521. (Pubitemid 28183374)
28. Matsumoto M, Funami K, Tanabe M, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol. 2003;171:3154-3162. (Pubitemid 37093540)
29. Lee H, Dunzendorfer S, Soldau K, et al. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity. 2006;24:153-163. (Pubitemid 43214585)
30. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA. 2006;103:8459-8464. (Pubitemid 43838477)
31. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101-105.
32. Hirabayashi K, Yano J, Inoue T, et al. Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res. 1999;59:4325-4333. (Pubitemid 29418751)
33. Yu J, Wheeler C, Zeltzer P, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61:842-847. (Pubitemid 32175145)